Table I.

Patient characteristicsa

ParameterNonrejection Transplant ControlsAcute RejectionBOS
No.787
Age58.4 years (1.9)48.3 years (3.7)48.6 years (7.3)
Gender58% male38% male58% male
42% female62% female42% female
Race86% Caucasian, 14% AAb75% Caucasian, 25% AA86% Caucasian, 14% AA
Type of transplant (single vs bilateral)86% single, 14% bilateral87% single, 13% bilateral72% single, 28% bilateral
Indication for lung transplant28% IPF37% IPF58% IPF
58% COPD50% COPD14% COPD
14% CF13% Pulm HTN28% CF
Average time of lavage from date of transplant1431 days (464)1203 days (299)3 mo before diagnosis: 878 days (205)
At time of diagnosis: 961 days (208)
Lung functionFEV1 = 1.47L (0.1)FEV1 = 1.57L (0.25)3 mo before diagnosis:
FEV1% = 56.2 (5.1)FEV1% = 55.9 (5.9)FEV1 = 2.17L (0.24)
FVC = 2.30L (0.08)FVC = 2.34L (0.29)FEV1% = 73.1 (8.4)
FVC% = 64.1 (5.2)FVC% = 58.4 (5.9)FVC = 2.94L (0.37)
FVC% = 72.0 (8.0)
At time of diagnosis:
FEV1 = 1.71L (0.21)
FEV1% = 58 (6.0)
FVC = 2.53L (0.28)
FVC% = 63.8 (7.2)
Immune suppression regimen72% Prograf, prednisone, and Cellcept63% Prograf, prednisone, and Cellcept86% Prograf, prednisone, and Cellcept
28% Prograf, prednisone, and azathioprine37% Gengraf, prednisone, and Cellcept14% Gengraf, prednisone, and Cellcept
  • a Patient populations are presented in three columns with SEMs noted in parentheses. Data are presented as either percentages or means ± SEM.

  • b AA, African American; Pulm HTN, pulmonary hypertension.